SunnyPharma provides independent health education for UK patients. The Mounjaro maintenance dose is the weekly tirzepatide dose you take after reaching your target weight, with the goal of keeping it there. This guide explains what the licensed maintenance doses are, how to find the right one for you, what the clinical evidence shows about stopping treatment, and what maintenance costs in the UK in 2026.
- Licensed UK maintenance doses: 5 mg, 10 mg, and 15 mg weekly
- Purpose: weight stability, not continued significant loss
- No fixed duration: treatment length depends on individual response and prescriber review
- SURMOUNT-4 evidence: patients who stopped tirzepatide regained an average of 14% of their starting body weight (Aronne et al., JAMA 2024)
- Stepping down is possible: many patients maintain results on a lower dose than the one they lost weight on
- The lowest effective dose is the right dose — this is a clinical principle, not just a cost consideration
What the Mounjaro Maintenance Dose Is
The maintenance dose is the weekly dose of Mounjaro (tirzepatide) you take once you have reached your target weight and want to stay there. It is distinct from the titration phase — the period of dose escalation from 2.5 mg upward — and distinct from continued weight loss treatment.
The UK Mounjaro Summary of Product Characteristics (SmPC) licences three doses for maintenance: 5 mg, 10 mg, and 15 mg weekly. The 2.5 mg, 7.5 mg, and 12.5 mg doses are titration strengths. Some prescribers use intermediate strengths off-label for maintenance in patients who find licensed doses too strong or poorly tolerated — but the standard pathway uses 5, 10, or 15 mg.
The Clinical Evidence for Maintenance — SURMOUNT-4
The SURMOUNT-4 trial (Aronne et al., JAMA, 2024) is the only randomised controlled trial specifically designed to test what happens when patients continue or stop tirzepatide after achieving weight loss.
After an open-label phase in which all participants lost weight on tirzepatide, participants were randomised to either continue the drug or switch to placebo for a further 52 weeks. The results were clear:
- Patients who continued tirzepatide lost a further 5.5% of their body weight over the follow-up period
- Patients who switched to placebo regained an average of 14% of their starting body weight
- The difference between the two groups was approximately 19.4 percentage points in body weight at 88 weeks
Why does weight return? This is a biological response, not a failure of willpower. Obesity involves persistent changes to appetite-regulating hormones, metabolic rate, and fat-storage signals. Tirzepatide suppresses these signals while you are taking it. When treatment stops, the signals reassert themselves — hunger returns, food noise increases, and the body works to restore its previous weight. This is why obesity guidelines in the UK, including NICE guidance, frame it as a chronic condition requiring long-term management.
Licensed vs Titration Doses — What Can Be Used for Maintenance
| Dose | Status | Use in maintenance |
|---|---|---|
| 2.5 mg | Titration dose | Not a licensed maintenance dose. Sometimes used off-label for very gradual step-down — prescriber decision only. |
| 5 mg | Licensed maintenance | Lowest licensed maintenance dose. Suitable for patients who reach their target weight at this level or who successfully step down from higher doses. |
| 7.5 mg | Titration dose | Not a licensed maintenance dose. May be used off-label by some prescribers as an intermediate step-down — clinical judgement required. |
| 10 mg | Licensed maintenance | Mid-range maintenance dose. Common for patients who lost weight on 10–15 mg and wish to step down one level while monitoring for regain. |
| 12.5 mg | Titration dose | Not a licensed maintenance dose. May be used off-label as an intermediate between 10 mg and 15 mg — prescriber decision. |
| 15 mg | Licensed maintenance | Maximum licensed dose. Used for maintenance when lower doses do not sufficiently control appetite or weight. |
Source: Mounjaro UK Summary of Product Characteristics (Eli Lilly / EMC). Off-label use of intermediate doses for maintenance is a clinical decision — discuss with your prescriber.
How to Find Your Maintenance Dose
There is no universal maintenance dose. The right dose is the lowest one that keeps your weight stable — typically defined as maintaining within 2–3% of your goal weight over a sustained period.
The process for finding it is the reverse of titration — gradual step-down rather than step-up:
- Reach your target weight on your current dose and remain stable for 4 to 8 weeks
- Discuss with your prescriber whether stepping down one dose level is appropriate
- If stepping down, monitor weight over 8 to 12 weeks at the lower dose
- If weight remains stable, the lower dose is your maintenance dose
- If weight begins to creep up — typically more than 2–3% over four weeks — return to the previous dose
The instinct to stay on the dose you lost weight on is understandable, but not always necessary. You no longer need the level of appetite suppression required to create a calorie deficit — only enough to prevent a calorie surplus. Many patients find a lower dose achieves this comfortably.
Signals your maintenance dose is working
- Weight remains within 2–3% of your goal weight over consecutive months
- Appetite and food noise remain manageable — you are not constantly fighting hunger
- Side effects are minimal or absent
- You are not losing further significant weight (maintenance, not further loss, is the goal)
What Happens When You Stop Mounjaro
Mounjaro has a half-life of approximately five days and remains measurably active in the body for 25 to 30 days after your last injection. After that, the appetite-suppressing effects cease entirely.
Most patients who stop experience:
- Return of hunger and increased food noise, often within a few weeks
- Feeling less satisfied by smaller portions
- Gradual weight regain, the pace of which depends on dietary habits established during treatment
The SURMOUNT-4 trial data confirms that stopping after reaching goal weight carries a substantial regain risk — averaging 14% of starting body weight over 52 weeks without the drug. This does not mean stopping is always the wrong decision: some patients who have established strong dietary habits and regular physical activity during treatment maintain their weight successfully without medication. However, these patients are the minority, and the decision should be made in consultation with a prescriber with a clear plan in place.
Do not stop Mounjaro abruptly without speaking to your prescriber. Stopping suddenly is not clinically dangerous, but without a plan for managing the return of appetite, weight regain is likely. Your prescriber can help you develop a step-down or stopping strategy that includes dietary and activity support.
How Long to Stay on Mounjaro Maintenance Dose
There is no fixed time limit. The duration depends on:
- How well habits are established: patients who have built consistent dietary patterns and regular physical activity during the weight loss phase are better positioned to reduce or stop medication than those who have not
- How long weight gain took to develop: patients whose weight gain was recent, moderate, or triggered by a specific event (stress, medication, pregnancy) tend to have better outcomes after stopping than those with longstanding obesity
- Individual biological response: some patients find appetite reliably returns without medication; others maintain well on lifestyle alone
- Prescriber review: NICE guidance (TA1026) applies to the weight loss phase rather than maintenance, but most UK prescribers review maintenance treatment at least every 3 to 6 months
Most patients who reach their goal weight on Mounjaro do so within 1 to 2 years. Many stay on maintenance for a further 1 to 2 years. Some continue longer because their weight and appetite are not reliably controlled without the medication — which, given SURMOUNT-4’s evidence, is a clinically supported reason to continue.
Mounjaro Maintenance Dose Cost UK — 2026
Private Mounjaro maintenance costs in the UK vary by dose and provider. The table below reflects approximate monthly costs from GPhC-registered UK pharmacies in June 2026.
| Maintenance dose | Monthly cost range | Annual cost (mid-range) | Saving vs 15 mg |
|---|---|---|---|
| 5 mg | £135–£240 | ~£2,220 | ~£1,500/year vs 15 mg mid-range |
| 10 mg | £165–£290 | ~£2,730 | ~£990/year vs 15 mg mid-range |
| 15 mg | £209–£340 | ~£3,294 | — |
Prices from GPhC-registered UK providers, June 2026. Annual cost calculated at mid-range monthly price × 12. Prices change frequently — verify directly with providers before ordering. See our Mounjaro price comparison UK guide for current provider-by-provider data.
Stepping down from 15 mg to 10 mg saves approximately £30 to £50 per month — £360 to £600 per year. This makes the step-down decision not only clinically sensible (find the lowest effective dose) but financially significant over a multi-year maintenance period.
Related UK GLP-1 Guides
Frequently Asked Questions
The Mounjaro maintenance dose is the weekly dose of tirzepatide you continue taking after reaching your target weight. Its purpose is weight stability, not further significant weight loss. In the UK, the licensed maintenance doses are 5 mg, 10 mg, and 15 mg weekly. The right dose is determined with your prescriber based on how well your weight remains stable and how you tolerate the medication.
The licensed UK maintenance doses are 5 mg, 10 mg, and 15 mg weekly. The 2.5 mg, 7.5 mg, and 12.5 mg strengths are titration doses. Some prescribers use intermediate strengths off-label for maintenance in individual patients, but the standard licensed pathway uses 5, 10, or 15 mg.
Clinical evidence shows significant weight regain after stopping tirzepatide. The SURMOUNT-4 trial (Aronne et al., JAMA 2024) found patients who stopped after reaching goal weight regained an average of 14% of their starting body weight by 88 weeks, compared to continued weight loss in those who stayed on treatment.
Yes. Many patients who reach their target weight at a higher dose find they can step down to a lower maintenance dose without regaining weight. The clinical principle is to find the lowest dose that keeps your weight stable. Moving from 15 mg to 10 mg, or 10 mg to 5 mg, is reasonable to explore with your prescriber, with monitoring over 8 to 12 weeks at the lower dose.
There is no fixed duration. Most patients who reach their goal weight do so within 1 to 2 years. Some stay on maintenance for a further 1 to 2 years; others continue long-term because their weight is not reliably controlled without the medication. Treatment length is always determined by your prescriber based on individual progress.
Monthly maintenance costs from GPhC-registered UK pharmacies in 2026: 5 mg approximately £135–£240, 10 mg approximately £165–£290, 15 mg approximately £209–£340. Stepping from 15 mg to 10 mg saves approximately £30–£50 per month. Confirm current prices directly with providers before ordering.
The transition typically occurs when you have reached your target weight or are very close to it and are maintaining stable results at your current dose. Most patients reach this point after 4 to 6 months of dose escalation. Your prescriber initiates the discussion — there is no automatic trigger.
Some patients continue to lose small amounts of weight early in the maintenance phase. However, the primary goal is weight stability. If you are aiming for further significant loss, discuss this with your prescriber — continuation of the titration phase or dose adjustment may be more appropriate.
Mounjaro remains active for 25 to 30 days after your last injection. After that, appetite-suppressing effects cease. Most patients experience a return of hunger, increased food noise, and reduced fullness — the biological mechanism behind post-treatment weight regain. The strength of this response varies between individuals.
The mechanism is the same. At maintenance, you no longer need appetite suppression to drive weight loss — only enough to prevent regain. This is why many patients can sustain results on a lower maintenance dose than the one they used to lose weight. The bar has shifted from creating a calorie deficit to preventing a calorie surplus.
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on peer-reviewed clinical trial data, manufacturer prescribing information, and NICE guidance. Key sources include SURMOUNT-4 (Aronne et al., JAMA 2024), SURMOUNT-1 (Jastreboff et al., NEJM 2022), the Mounjaro UK Summary of Product Characteristics (Eli Lilly / EMC), and NICE Technology Appraisal TA1026. Cost figures are cross-checked against GPhC-registered UK providers, June 2026. Dr. Swiggum’s review covers the clinical content. SunnyPharma does not prescribe or sell medications.
Read our editorial policy →Sources & References
- Aronne LJ et al. — SURMOUNT-4: Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA 2024;331(1):38–48: doi.org/10.1001/jama.2023.24945
- Jastreboff AM et al. — SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. NEJM 2022;387:205–216: nejm.org
- Eli Lilly — Mounjaro (tirzepatide) UK Summary of Product Characteristics (SmPC): medicines.org.uk
- NICE Technology Appraisal TA1026 — Tirzepatide for managing overweight and obesity (December 2023): nice.org.uk
- Horn DB et al. — Time to weight plateau with tirzepatide in SURMOUNT-1 and SURMOUNT-4. Clinical Obesity 2025;15(3):e12734: doi.org/10.1111/cob.12734
- MHRA — Mounjaro product information: gov.uk/mhra
- NHS England — Tier 3 weight management services commissioning guidance: england.nhs.uk
- General Pharmaceutical Council — Online pharmacy register: pharmacyregulation.org